Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on oncology therapeutics, announced that its annual meeting of shareholders will be held virtually at 9 a.m. PDT on June 29, 2026. Meeting materials will be mailed following finalization and filing with the Securities and Exchange Commission. The company also disclosed that its 2025 annual report included an audit report containing a going concern explanatory paragraph from its independent registered public accounting firm, as required under Section 610(b) of the NYSE American Company Guide. The disclosure does not reflect any change or amendment to previously filed financial statements.
The going concern notice indicates substantial doubt about the company's ability to continue as a going concern, a common disclosure for early-stage biotech firms with limited revenue and significant research and development expenses. This announcement comes as Kairos Pharma advances its lead candidate, ENV-105, an antibody targeting CD105, a protein identified as a key driver of drug resistance and disease relapse in cancer. ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the U.S. Food and Drug Administration or any other comparable foreign regulator.
The virtual annual meeting format reflects a trend among public companies to increase shareholder accessibility. Shareholders should review the meeting materials for details on proposals and voting procedures. The going concern disclosure, while not altering previously filed financials, underscores the financial challenges typical for clinical-stage companies that have yet to generate product revenue. Kairos Pharma's ability to continue operations depends on securing additional financing, successful clinical trial outcomes, and eventual regulatory approval of its drug candidates. For more information, the full press release is available at https://ibn.fm/sQ0pm.
Kairos Pharma, based in Los Angeles, California, utilizes structural biology to overcome drug resistance and immune suppression in cancer. The company's focus on CD105 positions it in a competitive oncology landscape, where targeted therapies aim to improve patient outcomes in hard-to-treat cancers. Investors and stakeholders can find the latest news and updates on the company's newsroom at https://ibn.fm/KAPA.
